RxDoctor Payments Data

Sarah Davidson, PA

Medical · San Antonio, TXNPI 1437578648

Payments from drug & device makers

$7,769in general payments, 2019–2025

Across 485 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$986
  • Amgen$877
  • Novo Nordisk$869
  • GSK$589
  • Lilly USA, LLC$558
  • Pfizer$387
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$7,769100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,769 in reported general payments places this provider in the 90th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas

Medicare billing

Part B allowed, 2024
$2,322
Medicare patients
15
Services billed
39

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide89$112,995
MounjaroTirzepatide49$72,715
FarxigaDapagliflozin Propanediol27$35,557
JanuviaSitagliptin Phosphate14$20,483
EliquisApixaban22$18,478
Levothyroxine Sodium211$2,300
Nebivolol Hcl26$2,170
Rosuvastatin Calcium188$2,009
ProgesteroneProgesterone, Micronized21$1,881
Atorvastatin Calcium183$1,719
Bupropion XlBupropion Hcl53$1,464
Fluticasone Propionate71$1,434
Estradiol17$1,386
Gabapentin53$1,229
Ibandronate Sodium17$1,165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$869$112,99589 claims
Lilly USA, LLCMounjaro$558$72,71549 claims
AstraZenecaFarxiga$309$35,55727 claims
MerckJanuvia$179$20,48314 claims
PfizerEliquis$387$18,47822 claims
Sanofi-aventis U.S. LLCLantus$21$88312 claims
Acella Pharmaceuticals, LLCNp Thyroid$20$66612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,490 medical providers in Texas.

Other medical in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →